Financial Data and Key Metrics Changes - The company recorded revenue of $2.1 million for Q2 2025, down from $5 million in Q2 2024, primarily due to short-term delays in multi-device enterprise health sales, partially offset by higher sales of the Ekso Indigo personal device [8] - Gross profit for Q2 2025 was $800,000, representing a gross margin of approximately 40%, compared to a gross profit of $2.6 million and a gross margin of 53% for the same period in 2024 [8] - Operating expenses for Q2 2025 were $4.8 million, a 4% improvement from $5 million in Q2 2024 [9] - The net loss applicable to common stockholders for Q2 2025 was $2.7 million, or $1.24 per share, compared to a net loss of $2.4 million, or $1.99 per share, for the same period in 2024 [9] Business Line Data and Key Metrics Changes - The legacy enterprise health product, primarily the EksoNR device, faced revenue declines, while the Ekso Indigo personal device saw increased sales, contributing to a 50% growth in personal health product revenues in the first half of 2025 [13][21] - Despite total revenues for the first six months of 2025 being down 38% compared to the same period in 2024, personal health product revenues grew by more than 50% [13] Market Data and Key Metrics Changes - The company is experiencing a trend of lower but steady growth in the legacy enterprise health business, counterweighted by growth in personal health from the Ekso Indigo device [13] - The company has developed a pipeline of over 45 Medicare beneficiaries qualified for the Ekso Indigo personal device, up more than 200% from the end of 2024 [16] Company Strategy and Development Direction - The company is focusing on a scalable go-to-market strategy for the Ekso Indigo personal device, supported by new distribution partners and educational initiatives like Ekso University [12][21] - A strategic initiative is underway to build a proprietary foundation model for human motion in physical rehabilitation, integrating new AI capabilities across the product portfolio [17][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the revenue shortfall in Q2 2025 does not reflect the overall health of the business and anticipates closing a significant portion of deferred sales in the second half of the year [11][20] - The company is actively working with partners to navigate market access and reimbursement processes, which are critical for the commercialization of personal devices [35] Other Important Information - The company joined the NVIDIA Connect program to enhance product development and cost efficiency, aiming to leverage AI in exoskeleton technology [17][19] - The company is working with Pria Healthcare to improve market access and reimbursement processes for the Ekso Indigo personal device [15][36] Q&A Session Summary Question: Can you quantify the deferred sales on the Enterprise Health side? - Management indicated that two multi-unit device sales fell out of Q2, with one being an international order delayed due to regulatory challenges and the other a North American order expected to occur in Q3, totaling approximately $1.4 million [24] Question: When do you expect the Indigo Personal to overtake the Enterprise Health business? - Management believes that by 2025, the contribution from personal health products will increase to about 25% of total revenue, with expectations to overtake enterprise health by 2027 [26] Question: How is the process of nailing down the patient profile progressing? - Management reported positive outcomes from appeals processes, with claims being approved when presented to administrative law judges, indicating that the technology is deemed medically necessary [29] Question: Will Ekso University focus solely on exoskeletons? - Management stated that while the initial courses focus on exoskeleton technology, future content will cover a wide range of neuro rehabilitation topics [30] Question: How many enterprise clients utilize federal grants? - Management estimated that approximately 10% of enterprise customers rely on federal or outside grants to fund their technology [41]

Investor Presentation July 2025 Disclaimer This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and expectations of management wit ...

Company Overview - Ekso Bionics is a developer of exoskeleton solutions designed to augment human strength, endurance, and mobility[6] - The company has deployed over 900 devices in more than 450 centers worldwide[7, 12, 37] Financial Performance & Market Opportunity - Ekso Bionics generated $15.4 million in clinical revenue in 2023, out of $18.2 million total revenue[6] - The company received CMS reimbursement for Ekso Indego Personal at $91,000[7, 50] - The total potential addressable market for personal mobility exoskeletons is estimated at $13.1 billion, including potential future neurodegenerative indications in the USA[55] - The long-term potential market for general debility usage is estimated at $34 billion, based on 1.5 million manual wheelchair users in the USA[55] - The company's revenue for FY 2023 was $18.3 million, a 42% increase compared to $13.0 million in FY 2022[71, 75] Market Reach & Strategy - The company leverages a clinical installed base of approximately 260 US centers to reach patients with spinal cord injuries[7] - Ekso Bionics is focused on achieving positive operating cash flow through scaling revenue growth and improving operating efficiencies[7, 82] - The company is expanding its market reach across the care continuum, from outpatient to home, with the Indego product line[76] - The potential market opportunity for the EVO industrial exoskeleton in targeted segments is greater than $8 billion annually[66]

Financial Data and Key Metrics Changes - The company recorded revenue of $3.4 million in Q1 2025, down from $3.8 million in Q1 2024, attributed to capital budget impacts from certain inpatient rehabilitation facilities related to the EksoNR enterprise health product [7] - Gross profit for Q1 was $1.8 million, representing a gross margin of approximately 54%, compared to a gross profit of $2 million and a gross margin of 52% in Q1 2024 [8] - Operating expenses for Q1 2025 were $5.3 million, essentially unchanged from $5.2 million in Q1 2024 [8] - Net loss applicable to common stockholders for Q1 2025 was $2.9 million or $0.12 per share, compared to a net loss of $3.4 million or $0.20 per share in Q1 2024 [8] - As of March 31, 2025, the company had cash and restricted cash of $8.1 million, up from $6.5 million at the end of 2024 [9] Business Line Data and Key Metrics Changes - The primary end market for the company's exoskeleton technology is healthcare, with two segments: enterprise health and personal health [6] - The legacy enterprise health products, mainly the EksoNR device, faced revenue declines due to budget impacts, while the Ekso Indigo personal device saw growth [10][11] - The company developed a pipeline of over 35 Medicare beneficiaries qualified for the Ekso Indigo Personal in 2025, a 37% increase from the previous quarter [12] Market Data and Key Metrics Changes - The company noted softness in the legacy enterprise business due to macroeconomic uncertainties affecting customer capital budgets [10] - The engagement with Priya Healthcare and the establishment of new distribution partnerships are expected to enhance market access and claims processing for the Ekso Indigo Personal [11][15] Company Strategy and Development Direction - The company is focusing on building a scalable go-to-market strategy for the Ekso Indigo Personal, leveraging partnerships with distribution networks [14][15] - The strategy includes working closely with neuro rehabilitation partners and enhancing education efforts for appropriate patient selection [11] - The company anticipates that the majority of revenue in 2025 will still come from enterprise health, but expects increasing contributions from personal health products [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of economic uncertainties on capital budgets, particularly in Q1, but expressed optimism about the pipeline and future contributions from personal health products [10][27] - The management team believes that the operational improvements and cost controls will support gross margins as revenues expand [29] Other Important Information - The company is navigating complexities in coding, coverage, and payment to enhance access to its exoskeleton technology for individuals with mobility challenges [13] - The partnerships with National Seating and Mobility and Bionic P and O are expected to broaden access to the Ekso Indigo Personal across the U.S. [15][36] Q&A Session Summary Question: How should investors think about where the patients will fall this year in terms of the Indigo Personal? - Management expects that enterprise products will represent 75% to 80% of the business, with solid contributions from personal products growing quarter over quarter [19] Question: Any more color on how things are going with claims submissions? - Management has learned from past claims and believes current submissions are comprehensive with a high probability of success [24] Question: What is the outlook on capital budgeting from IDNs? - Management noted softness in capital budgets in Q1 but expects solid contributions from renewals in 2025 [26] Question: Is the gross margin trending in the right direction? - Management believes that operational improvements will allow for higher gross margins as revenue increases [29]

Core Viewpoint - Ekso Bionics Holdings, Inc. reported its financial results for the first quarter of 2025, highlighting a decrease in revenue primarily due to lower sales of legacy devices, while also noting significant partnerships that may enhance future growth in the Personal Health products segment [1][4][11]. Financial Performance - The company recorded revenue of $3.4 million for the quarter ended March 31, 2025, down from $3.8 million in the same period in 2024, mainly due to lower sales of legacy EksoNR devices, although sales of Ekso Indego Personal devices increased [4]. - Gross profit for the first quarter was $1.8 million, with a gross margin of approximately 53.5%, compared to $2.0 million and a gross margin of 51.9% in the prior year, driven by cost savings in the supply chain [5]. - Sales and marketing expenses decreased to $1.7 million from $1.8 million year-over-year, attributed to lower headcount and travel expenses [6]. - Research and development expenses were $1.0 million, down from $1.1 million in the previous year, mainly due to reduced use of product development consultants [7]. - General and administrative expenses increased to $2.6 million from $2.3 million, primarily due to an impairment loss of an intangible asset and higher legal and audit costs [8]. - The net loss applicable to common stockholders was $2.9 million, or $0.12 per share, compared to a net loss of $3.4 million, or $0.20 per share, in the same quarter of 2024 [9]. Cash Flow and Position - The company used $2.0 million of net cash in operations for the first quarter of 2025, a decrease from $3.5 million in the same period in 2024 [9]. - As of March 31, 2025, the company had cash and restricted cash totaling $8.1 million, an increase from $6.5 million at the end of 2024 [9][16]. Strategic Partnerships - Ekso Bionics has formed partnerships with National Seating & Mobility (NSM) and Bionic Prosthetics & Orthotics Group (Bionic P&O), which are expected to enhance access to the Ekso Indego Personal device in the complex rehabilitation technology and orthotics and prosthetics markets, respectively [3][11].